Procept Biorobotics Corp. (PRCT)
NASDAQ:PRCT
Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$25.14
-$0.85(-0.97%)
At close: 4:00 PM EST
$25.14
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$19.35 - $62.17
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.64M
Market Cap
$1.24B
Enterprise Value$996.20M
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jul 30, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume1,973,836
30 Day Avg. Volume1,642,158
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit4.91
Enterprise Value/Ebitda-10.82
Forecast
1Y Price Target
$29.20Price Target Upside16.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$398.94M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueHigh-margin, per-procedure consumables create a recurring revenue stream that scales with procedure volume and installed base growth. This model smooths revenue cadence versus pure capital sales and supports sustainable unit economics as procedures expand across end customers and geographies.
Procedure Adoption & Installed-base GrowthRobust procedure growth and sizable FY guidance indicate durable clinical adoption, which drives recurring consumable demand and future system placements. Rapid U.S. uptake plus international rollouts (e.g., U.K. NHS adoption) increase addressable volume and long-term revenue visibility.
Improving Unit Economics & PricingSustained ~65% gross margins and recent ASP strength demonstrate improving unit economics and pricing power. High gross margins provide a structural buffer to absorb incremental tariff/COGS shocks and support eventual leverage to profitability as fixed costs scale with revenue.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates the business still requires external financing or sizable cash reserves to fund growth and clinical programs. Continued cash burn raises dilution and financing risk if revenue growth or margin expansion slows materially.
Large Operating And Net LossesDespite top-line momentum, substantial GAAP and adjusted losses show the cost base remains ahead of current revenue scale. Persistent negative profitability limits reinvestment flexibility and means the company must execute margin leverage or rely on external capital before achieving durable self-funded growth.
Tariff & Pricing Sustainability RisksRising tariff exposure increases gross-cost volatility and could erode margins if refunds or pass-throughs don't materialize. Separately, system ASP strength may be mix-dependent; if pricing softens with different buyers or replacements, both capital revenue and margin forecasts could be pressured.
PROCEPT BioRobotics News
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $19.35 and its highest was $62.17 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $1.24B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -0.46.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 56,918,842 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.20 (16.15% Upside)
$29.20 (16.15% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.59%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$29.20
▲(16.15% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.00% Insiders
27.16% Mutual Funds
39.57% Other Institutional Investors
13.83% Public Companies and
Individual Investors